Yunsoo Kim

Array ( [id] => 12157390 [patent_doc_number] => 20180028655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'Stable Aqueous Formulations of Adalimumab' [patent_app_type] => utility [patent_app_number] => 15/730399 [patent_app_country] => US [patent_app_date] => 2017-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 39945 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15730399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14291927 [patent_doc_number] => 10286071 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Syringe containing stable aqueous formulations of adalimumab [patent_app_type] => utility [patent_app_number] => 15/729243 [patent_app_country] => US [patent_app_date] => 2017-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 35631 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15729243 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14291929 [patent_doc_number] => 10286072 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Methods of manufacturing stable aqueous formulations of adalimumab [patent_app_type] => utility [patent_app_number] => 15/729295 [patent_app_country] => US [patent_app_date] => 2017-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 35638 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15729295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408083 [patent_doc_number] => 20200024363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => REDUCED VISCOSITY PROTEIN PHARMACEUTICAL FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/337325 [patent_app_country] => US [patent_app_date] => 2017-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -77 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17648553 [patent_doc_number] => 11351256 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => Room temperature stable lyophilized protein [patent_app_type] => utility [patent_app_number] => 15/727457 [patent_app_country] => US [patent_app_date] => 2017-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 16341 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15727457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13659179 [patent_doc_number] => 10159733 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-25 [patent_title] => Stable aqueous formulations of adalimumab [patent_app_type] => utility [patent_app_number] => 15/726215 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 35612 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13659177 [patent_doc_number] => 10159732 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-25 [patent_title] => Stable aqueous formulations of adalimumab [patent_app_type] => utility [patent_app_number] => 15/726165 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 35635 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12217570 [patent_doc_number] => 20180055929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'Stable Aqueous Formulations of Adalimumab' [patent_app_type] => utility [patent_app_number] => 15/726195 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 39916 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12183914 [patent_doc_number] => 20180042850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'Pharmaceutical Composition of Killed Cells with Substantially Retained Immunogenicity' [patent_app_type] => utility [patent_app_number] => 15/722511 [patent_app_country] => US [patent_app_date] => 2017-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 8304 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15722511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16665133 [patent_doc_number] => 10934366 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-02 [patent_title] => Protein-nanoparticle conjugate purification methods [patent_app_type] => utility [patent_app_number] => 15/714736 [patent_app_country] => US [patent_app_date] => 2017-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4654 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15714736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435467 [patent_doc_number] => 20200031917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => ANTIBODY AND PROTEIN THERAPUTIC FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/337103 [patent_app_country] => US [patent_app_date] => 2017-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12117350 [patent_doc_number] => 20180000935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'Stable Antibody Containing Compositions' [patent_app_type] => utility [patent_app_number] => 15/709530 [patent_app_country] => US [patent_app_date] => 2017-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 12612 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15709530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12580809 [patent_doc_number] => 20180085432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => STING (Stimulator of Interferon Genes), A Regulator of Innate Immune Responses [patent_app_type] => utility [patent_app_number] => 15/706222 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15706222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12621606 [patent_doc_number] => 20180099032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => VACCINE COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/705520 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15705520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464745 [patent_doc_number] => 20190184012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => NANOBODY BIOMEDICINE TRANSDERMAL ADMINISTRATION FORMULATION SYSTEM AND PREPARATION METHOD AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/068668 [patent_app_country] => US [patent_app_date] => 2017-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12603063 [patent_doc_number] => 20180092851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => Thermostable Vaccine Compositions and Methods of Preparing Same [patent_app_type] => utility [patent_app_number] => 15/694023 [patent_app_country] => US [patent_app_date] => 2017-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15694023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17192144 [patent_doc_number] => 11160876 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-02 [patent_title] => Methods and compositions for targeting t-cell cancers [patent_app_type] => utility [patent_app_number] => 16/330028 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14826 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16330028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786457 [patent_doc_number] => 20180153988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS [patent_app_type] => utility [patent_app_number] => 15/691266 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31433 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15691266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16854942 [patent_doc_number] => 20210155687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => DOSAGE REGIMEN [patent_app_type] => utility [patent_app_number] => 16/327751 [patent_app_country] => US [patent_app_date] => 2017-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16327751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12858118 [patent_doc_number] => 20180177880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => ANTI-CD3 ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 15/690192 [patent_app_country] => US [patent_app_date] => 2017-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15690192 [rel_patent_id] =>[rel_patent_doc_number] =>)